Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cognition Therapeutics Inc
(NQ:
CGTX
)
0.7380
-0.0205 (-2.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cognition Therapeutics Inc
< Previous
1
2
3
Next >
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
August 08, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
August 02, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
July 11, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
July 05, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
June 28, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
June 27, 2023
Call and webcast will take place at 8:00am ET
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
June 20, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
June 02, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
May 23, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
May 18, 2023
- First Human Evidence that CT1812 Selectively Engages Aβ Oligomers
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
May 01, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
April 19, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
April 12, 2023
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimer’s Disease, Dementia with Lewy Bodies and Geographic Atrophy
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
March 28, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
March 27, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
March 23, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
March 16, 2023
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ET
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
March 21, 2023
- CEO Participating on Panel Hosted by Alzheimer’s Drug Discovery Foundation -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
March 16, 2023
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
March 15, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference
March 07, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
February 22, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
February 21, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
December 22, 2022
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
December 21, 2022
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
February 09, 2023
Innovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
December 15, 2022
SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
December 01, 2022
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
November 28, 2022
Innovative trial addresses second most common dementia after Alzheimer’s disease, now enrolling patients at up to 30 activated sites across the USA
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.